Opinion|Videos|July 29, 2024
Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
A panel of experts discuss switching between different antihistimines and other medications when treating CSU patients.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- A significant number of patients with CSU do not respond adequately to antihistamines. What is your approach to switching between (or adding on) antihistamines and when do you switch to another class of medications?
- How does antihistamine switching and treatment selection correlate with timing of disease episodes?
- If patients aren’t responding well to antihistamines, which therapies do you use next? When do you consider using biologics? What considerations do you take into account and what ultimately is driving that decision?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
4
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
5